Immunex Corporation

Type: Company
Name: Immunex Corporation
Nationality: United States
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

PsA Outcomes Linked to Adalimumab Levels, Antibodies

Monitoring adalimumab ( Humira , AbbVie) serum levels and watching for the development of antidrug antibodies (ADA) might be the next step forward for improving outcomes in patients with psoriatic arthritis (PsA) treated with the biologic, researchers ... [Published Diabetes Care - Aug 26 2014]
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Amgen: A lesson in state's tax break policy

Amgen's Seattle campus was on the waterfront beyond the Amgen Helix Bridge over BNSF tracks. When the City of Seattle agreed to build an overpass for traffic to have access to the campus, the company built the pedestrian bridge. Flickr: Chas RedmondAmgen ... [Published Crosscut Seattle - Aug 23 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

BUDGET: Funding there if tax breaks are repealed

Re: “Do we fund schools first? Or mental health now?” ( editorial , 8-12).Adequate state funding for both education and mental health programs would be a lot easier if the Legislature repealed tax breaks that are no longer relevant.Example: Amgen has ... [Published Tacoma News Tribune - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Policyholder Takes the Insurer’s Bait and Loses Coverage

Beware the Trojan Horse: an agreement to defend based on reservations followed, in short order, by declaratory relief actions.  The policyholder’s defender may be in disguise.In an interesting Order coming from the United States District Court in Western ... [Published JD Supra - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

While Protesters Rage Against Tech Giants, Biotech Drives Quietly By

Not long ago, biotech made a lot of people angry. Up until 2005 or so, the annual Biotechnology Industry Organization conference attracted large street protests, which in turn attracted cops in riot gear in some cases (see San Francisco, 2004) as well ... [Published Xconomy - Aug 12 2014]
First reported Aug 09 2014 - Updated Aug 09 2014 - 1 reports

Theravance appoints Michael W. Aguiar as president, CEO

News and views on the clinical trials industry Friday, August 8, 2014 12:29 PMTheravance  has appointed Michael W. Aguiar as president and CEO effective August 15, and as a member of the board of directors effective immediately. Aguiar plans to continue ... [Published Center Watch - Aug 09 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 2 reports

South San Francisco's Theravance, Inc. Brings In A New CEO

Theravance, Inc. Appoints Michael W. Aguiar As President And Chief Executive OfficerSOUTH SAN FRANCISCO, CA--(MARKETWIRED – AUGUST 6, 2014) – Theravance, Inc. (NASDAQ: THRX) (“Theravance” or “Company”) today announced that its Board of Directors has appointed ... [Published BioSpace - Aug 06 2014]
First reported Aug 03 2014 - Updated Aug 03 2014 - 1 reports

Amgen’s exit a symbol of our biotech status

Is it about them? Or is it about us?These are the natural questions after a traumatic breakup, such as Amgen announcing it will vacate its entire Seattle-area operations, including the showpiece buildings that face Elliott Bay.And traumatic it was. I ... [Published Seattle Times - Aug 03 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

CDRD Ventures Inc. Boosts Commercialization Power with New Additions to Senior Management Team

) - CDRD Ventures Inc. (CVI), the commercialization vehicle of The Centre for Drug Research and Development (CDRD), Canada's fully-integrated national drug development and commercialization centre, is pleased to announce the appointment of Mr. Michael ... [Published MarketWired - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 1 reports

BRIEF: Amgen will shut Seattle, Bothell operations

July 29--Amgen said Tuesday it will close its operations in Seattle and Bothell as part of a companywide retrenchment that includes more than 2,400 job cuts.The biotechnology giant, based in Thousand Oaks, Calif., said it will begin the workforce reductions ... [Published Pharmaceutical & Medical Packaging News - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 2 reports

Amgen Pleases the Street -- but Will Layoffs Keep Critics at Bay?

NEW YORK (TheStreet) -- Amgen,  the sprawling biotechnology company, pleased investors with higher profits and big layoffs yesterday, but its moves will not quiet those who want a more basic restructuring.The maker of the osteoporosis drug Prolia said ... [Published West Hartford News - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Seattle Jobs? Big Biotech Gives And Takes Away (Mostly The Latter)

Reporting a 25 percent jump in profits, Amgen (NASDAQ: AMGN) also dealt a blow to Seattle’s biotech job market today. The Thousand Oaks, CA-based biotech drug maker announced a huge round of job cuts, 12 to 15 percent of its staff worldwide, and a shuttering ... [Published Xconomy - Jul 30 2014]

Quotes

...He said that gastroenterologists are more often measuring adalimumab levels to guide therapy in diseases such as inflammatory bowel disease. "This article is making me think about learning how to make better use of the laboratory services that do provide tests for adalimumab levels and for antidrug antibodies" he said
...developing an exceptionally talented finance organization," said Michael W Aguiar, Senior Vice President and Chief Financial Officer of Theravance. "Looking forward, we will work closely with GSK with the goal of maximizing the value of the respiratory programs partnered with GSK, focus on reducing Theravance's overall cost of capital, and build a royalty management business with the goal of providing returns to our stockholders."
Natalie Dakers, President and CEO of CVI commented, "Both these individuals represent highly-valuable additions to the CVI team as we amplify our focus on commercial outcomes, and move forward to our next stage of development as an organization. Their collective experience and track records are truly impressive as they have each demonstrated impactful results for the organizations they have served. We are excited to be able to now draw upon their distinct experience to build new companies and advance cutting-edge technologies into the clinic - and in doing so, making a real difference to Canada's health sciences industry" she said
...which has grown through acquisitions like the 2002 deal in which it bought Seattle-based Immunex, said it plans to consolidate operations in "the biotechnology hubs of South San francisco and Cambridge, Mass" but will keep its headquarters in Southern California

More Content

All (25) | News (24) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
OMBP: Omni Bio Executing On Development Plan [Published Yahoo! Finance - Aug 26 2014]
PsA Outcomes Linked to Adalimumab Levels, Antib... [Published Diabetes Care - Aug 26 2014]
Amgen: A lesson in state's tax break policy [Published Crosscut Seattle - Aug 23 2014]
BUDGET: Funding there if tax breaks are repealed [Published Tacoma News Tribune - Aug 13 2014]
Policyholder Takes the Insurer’s Bait and Loses... [Published JD Supra - Aug 13 2014]
While Protesters Rage Against Tech Giants, Biot... [Published Xconomy - Aug 12 2014]
Theravance appoints Michael W. Aguiar as presid... [Published Center Watch - Aug 09 2014]
South San Francisco's Theravance, Inc. Brings I... [Published BioSpace - Aug 06 2014]
Theravance, Inc. Appoints Michael W. Aguiar as ... [Published Market Pulse Navigator - Aug 06 2014]
A merger with the power to help kids | Jerry Large [Published Seattle Times - Aug 04 2014]
Amgen’s exit a symbol of our biotech status [Published Seattle Times - Aug 03 2014]
CDRD Ventures Inc. Boosts Commercialization Pow... [Published MarketWired - Jul 31 2014]
West Coast Biotech Roundup: Amgen Layoffs, Aval... [Published Xconomy - Jul 31 2014]
BRIEF: Amgen will shut Seattle, Bothell operations [Published Pharmaceutical & Medical Packaging News - Jul 30 2014]
Amgen Pleases the Street -- but Will Layoffs Ke... [Published West Hartford News - Jul 30 2014]
VBI Vaccines: A Company Ready For Breakthrough [Published Seeking Alpha - Jul 30 2014]
Amgen Pleases the Street -- but Will Layoffs Ke... [Published TheStreet.com - Jul 30 2014]
Seattle Jobs? Big Biotech Gives And Takes Away ... [Published Xconomy - Jul 30 2014]
Stem cell research advocate to speak at Pregnan... [Published South Whidbey Record - May 14 2014]
Ultragreen building is ready for challenge | Su... [Published Seattle Times - Apr 27 2014]
Cloned transmembrane receptor for 24-hydroxylat... [Published PharmCast - Mar 16 2014]
Catalent Announces Two Senior Appointments to E... [Published PRWeb - Feb 26 2014]
2013: The year's biggest Pharmaceutical Technol... [Published Pharmaceutical Technology - Jan 08 2014]
Cell-permeabilising peptides and polypeptides f... [Published PharmCast - Dec 01 2013]
Amgen planning to buy Onyx for about $10.4 billion [Published Topnews.in - Aug 26 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.